Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation

Obesity Clinical Trial

— LIPOGAIN-2  

Official title:

Role of Fatty Acids in Skeletal Muscle Hypertrophy and Ectopic Fat Accumulation During Overfeeding (LIPOGAIN-2)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02211612
• Other study ID #: LIPOGAIN-2
• Status: Completed
• Phase: N/A
• First received: August 6, 2014
• Last updated: October 25, 2016
• Start date: September 2014
• Est. completion date: June 2015

Study information

• Verified date: October 2016
• Source: Uppsala University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Regional Ethical Review Board
• Study type: Interventional

Clinical Trial Summary

To investigate metabolic and molecular response to fatty acid-specific overfeeding in overweight subjects, in relation to changes in ectopic fat, lean tissue mass and insulin sensitivity

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 30 Years to 50 Years

Eligibility

Inclusion Criteria:

• Body mass index 25-32

Exclusion Criteria:

• Type 2 diabetes

• Type 1 diabetes

• Kidney disease

• Liver disease

• Abnormal clinical chemistry at screening

• Intense physical exercise > 2 hours per week

• Use of statins or drugs affecting energy metabolism

• Use of extreme diets

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Body Composition
• Ectopic Fat
• Muscle Mass
• Obesity
• Overfeeding

Intervention

Dietary Supplement:
• PUFA-group

• SFA-group

Locations

Country	Name	City	State
Sweden	Uppsala University; Clinical nutrition and metabolism; Dept of public health and caring sciences	Uppsala	Please Select

Sponsors (2)

Lead Sponsor	Collaborator
Uppsala University	Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Circulating hormones and molecular analyses in muscle and fat tissue	Serum hormones including prolactin, tyroxin, T3, cortisol, growth hormone, Insulin growth factor-1. Fat cell morphology assessment in fat tissue, and gene and protein expression, DNA methylation analyses in fat and muscle tissue, palmitate tracer uptake in liver using positron emission tomography	10 weeks	No
Primary	Change in lean tissue mass	Assessed by magnetic resonance imaging (MRI) and air displacement plethysmography (BodPod)	10 weeks	No
Secondary	Change in hepatic fat content	Assessed by magnetic resonance imaging (MRI)	10 weeks	No
Secondary	Change in visceral adipose tissue (VAT)	Assessed by magnetic resonance imaging (MRI)	10 weeks	No
Secondary	Change in total adipose tissue	Assessed by magnetic resonance imaging (MRI)	10 weeks	No
Secondary	Change in pancreatic fat	Assessed by MRI	10 weeks	No
Secondary	Change in insulin sensitivity	Assessed by oral glucose tolerance test (OGTT)	10 weeks	No
Secondary	Change in plasma lipids	Plasma cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, apolipoprotein B, apolipoprotein A1, free fatty acids, glycerol, proprotein convertase subtilisin/kexin type 9	10 weeks	No
Secondary	Change in circulating inflammation and coagulation markers	Plasma tumor necrosis factor-receptor 2, Interleukin receptor 1 antagonist, C-reactive protein, fibrinogen, adhesion molecules	10 weeks	No